Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Pacira BioSciences (PCRX) Acquisitions (2019 - 2026)

Pacira BioSciences has reported Acquisitions over the past 3 years, most recently at $335000.0 for Q1 2026.

For Q1 2026, Acquisitions fell 97.99% year-over-year to $335000.0; the TTM value through Mar 2026 reached $335000.0, down 97.99%, while the annual FY2025 figure was $16.7 million, N/A changed from the prior year.
Acquisitions for Q1 2026 was $335000.0 at Pacira BioSciences, down from $16.7 million in the prior quarter.
Over five years, Acquisitions peaked at $16.7 million in Q1 2025 and troughed at $335000.0 in Q1 2026.